Synthesis, shedding, and intercellular transfer of human medulloblastoma gangliosides: abrogation by a new inhibitor of glucosylceramide synthase.
The biological activity of human medulloblastoma tumor gangliosides very likely involves the interaction of these molecules with host cells in the tumor microenvironment. To trace the hypothesized intercellular transfer of shed medulloblastoma gangliosides, we used an in vitro dual-chamber culture system in which the tumor cells, the shed gangliosides, and the target cells to which they might bind would not be perturbed during the transfer process. We observed that under these unmanipulated conditions, gangliosides were shed by the Daoy medulloblastoma cell line (approximately 300 pmol/10[8] cells/h), traversed the chamber membrane, and stably bound to the target fibroblasts at the very high density of 10(7) molecules per cell within 48 h. To determine if this substantial intercellular transfer of shed gangliosides, with its potential of modifying target cell function, could be blocked, we evaluated a new inhibitor of glucosylceramide synthase, DL-threo-1-phenyl-2-hexadecanoylamino-3-pyrrolidino-1-propanol (PPPP). PPPP (1.0 microM) reduced (90%) Daoy cell ganglioside content strikingly, without causing toxicity or inhibiting cell proliferation. Subsequently, ganglioside shedding by the medulloblastoma cells was diminished significantly (to approximately 50 pmol/10[8]/h), and binding of radiolabeled shed medulloblastoma gangliosides to target fibroblasts was consequently almost completely abrogated. We conclude that the shedding and transfer of potentially biologically active human medulloblastoma gangliosides can be diminished effectively by PPPP.
Olshefski
R
R
Children's Research Institute, and Department of Pediatrics, George Washington University School of Medicine, Washington, DC 20010-2970, USA.
Ladisch
S
S
D001665:Binding Sites; D002450:Cell Communication; D002460:Cell Line; D002462:Cell Membrane / Q000378:metabolism; D002528:Cerebellar Neoplasms / Q000378:metabolism* / Q000503:physiopathology; D018920:Coculture Techniques; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005347:Fibroblasts / Q000378:metabolism; D005732:Gangliosides / Q000096:biosynthesis / Q000378:metabolism*; D005964:Glucosyltransferases / Q000037:antagonists & inhibitors*; D006801:Humans; D007700:Kinetics; D008527:Medulloblastoma / Q000378:metabolism* / Q000503:physiopathology; D011412:Propanolamines / Q000494:pharmacology*; D011759:Pyrrolidines / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
C110417:1-phenyl-2-hexadecanoylamino-3-pyrrolidino-1-propanol; D004791:Enzyme Inhibitors; D005732:Gangliosides; D011412:Propanolamines; D011759:Pyrrolidines; D005964:Glucosyltransferases; C023246:ceramide glucosyltransferase